Nemonapride
Clinical data | |
---|---|
Trade names | Emilace (JP) |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 75272-39-8 |
PubChem (CID) | 4452 |
IUPHAR/BPS | 983 |
ChemSpider | 4297 |
UNII | Q88T5P3444 |
KEGG | D01468 |
ChEBI | CHEBI:64217 |
ChEMBL | CHEMBL20734 |
ECHA InfoCard | 100.215.765 |
Chemical and physical data | |
Formula | C21H26ClN3O2 |
Molar mass | 387.90 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Nemonapride (エミレース, Emilace (JP)) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist. It has affinity for sigma receptors.
See also
References
This article is issued from Wikipedia - version of the 5/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.